FASEB J. Thermo Fisher Scientific
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Bilbao, G.
Right arrow Articles by Curiel, D. T.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Bilbao, G.
Right arrow Articles by Curiel, D. T.

The FASEB Journal, Vol 11, 624-634, Copyright © 1997 by The Federation of American Societies for Experimental Biology

REVIEWS

Adenoviral/retroviral vector chimeras: a novel strategy to achieve high- efficiency stable transduction in vivo

G Bilbao, M Feng, C Rancourt, WH Jackson Jr and DT Curiel
Gene Therapy Program, Comprehensive Cancer Center, University of Alabama at Birmingham, 35294-3300, USA.

Gene therapy to correct defective genes requires efficient gene delivery and long-term gene expression. Realization of both goals with available vector systems has so far not been achieved. As a novel approach to solve this problem, we have developed a chimeric viral vector system that exploits favorable aspects of both adenoviral and retroviral vectors. In this schema, adenoviral vectors induce target cells to function as transient retroviral producer cells in vivo. The progeny retroviral vector particles can then effectively achieve stable transduction of neighboring cells. In this system, the nonintegrative adenoviral vector is rendered functionally integrative via the intermediate generation of an induced retroviral producer cell. Such chimeric vectors may now allow realization of the requisite goals for specific gene therapy applications.


This article has been cited by other articles:


Home page
 J. Virol.Home page
S. Kubo and K. Mitani
A New Hybrid System Capable of Efficient Lentiviral Vector Production and Stable Gene Transfer Mediated by a Single Helper-Dependent Adenoviral Vector
J. Virol., March 1, 2003; 77(5): 2964 - 2971.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
S. A. Vorburger and K. K. Hunt
Adenoviral Gene Therapy
Oncologist, February 1, 2002; 7(1): 46 - 59.
[Abstract] [Full Text] [PDF]

Home page
 J. Virol.Home page
Q. Zhong, P. Oliver, W. Huang, D. Good, V. La Russa, Z. Zhang, J. R. Cork, R. W. Veith, C. Theodossiou, J. K. Kolls, et al.
Efficient c-kit Receptor-Targeted Gene Transfer to Primary Human CD34-Selected Hematopoietic Stem Cells
J. Virol., November 1, 2001; 75(21): 10393 - 10400.
[Abstract] [Full Text] [PDF]

Home page
 HypertensionHome page
A. S. Pachori, M. J. Huentelman, S. C. Francis, C. H. Gelband, M. J. Katovich, and M. K. Raizada
The Future of Hypertension Therapy: Sense, Antisense, or Nonsense?
Hypertension, February 1, 2001; 37(2): 357 - 364.
[Abstract] [Full Text] [PDF]

Home page
 GutHome page
K SHETTY, G Y WU, and C H WU
Gene therapy of hepatic diseases: prospects for the new millennium
Gut, January 1, 2000; 46(1): 136 - 139.
[Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1997 by The Federation of American Societies for Experimental Biology.